Get started
SARTORIUS STEDIM BIOTECH S.A.SARTORIUS STEDIM BIOTECH S.A.SARTORIUS STEDIM BIOTECH S.A.

SARTORIUS STEDIM BIOTECH S.A.

No trades
See on Supercharts
Overview
Financials News Ideas Technicals Forecast

56S1 chart

Upcoming earnings

Next report date
Report period
Q2 2024
EPS estimate
1.06EUR
Revenue estimate
‪706.12 M‬EUR

Key stats

Market capitalization
‪20.27 B‬EUR
Dividend yield (indicated)
0.33%
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
2.75EUR
Net income (FY)
‪309.70 M‬EUR
Revenue (FY)
‪2.78 B‬EUR
Shares float
‪29.47 M‬
Beta (1Y)
1.88

About SARTORIUS STED BIO

Sector
Health Technology
Industry
Medical Specialties
CEO
René Fáber
Website
sartorius.com
Headquarters
Aubagne
Employees (FY)
‪10.66 K‬
Founded
1978
ISIN
FR0013154002
FIGI
BBG000R5C8S7
Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. The firm offers a broad portfolio of products that focuses on all steps in the manufacture of a biopharmaceutical, as well as in process development as prerequisite procedures. Its technologies cover inter alia, cell line technologies, cell culture media, bioreactors, and a wide range of products for separation, purification, and concentration of biological intermediates and finished products, as well as solutions for storage and transportation. It also offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. The company was founded on September 28, 1978 and is headquartered in Aubagne, France.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas

See all ideas 

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of 56S1 is 205.30 EUR — it has increased by 1.99% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange SARTORIUS STEDIM BIOTECH S.A. stocks are traded under the ticker 56S1.
SARTORIUS STEDIM BIOTECH S.A. is going to release the next earnings report on Jul 19, 2024. Keep track of upcoming events with our Earnings Calendar.
56S1 stock is 3.40% volatile and has beta coefficient of 1.88. Check out the list of the most volatile stocks — is SARTORIUS STEDIM BIOTECH S.A. there?
56S1 earnings for the last quarter are 0.72 EUR per share, whereas the estimation was 0.80 EUR resulting in a −9.63% surprise. The estimated earnings for the next quarter are 0.90 EUR per share. See more details about SARTORIUS STEDIM BIOTECH S.A. earnings.
SARTORIUS STEDIM BIOTECH S.A. revenue for the last quarter amounts to ‪706.40 M‬ EUR despite the estimated figure of ‪679.21 M‬ EUR. In the next quarter revenue is expected to reach ‪718.95 M‬ EUR.
Yes, you can track SARTORIUS STEDIM BIOTECH S.A. financials in yearly and quarterly reports right on TradingView.
56S1 stock has risen by 0.29% compared to the previous week, the month change is a 22.59% fall, over the last year SARTORIUS STEDIM BIOTECH S.A. has showed a 13.23% decrease.
56S1 net income for the last quarter is ‪56.10 M‬ EUR, while the quarter before that showed ‪39.80 M‬ EUR of net income which accounts for 40.95% change. Track more SARTORIUS STEDIM BIOTECH S.A. financial stats to get the full picture.
Today SARTORIUS STEDIM BIOTECH S.A. has the market capitalization of ‪20.27 B‬, it has decreased by 22.18% over the last week.
Yes, 56S1 dividends are paid annually. The last dividend per share was 0.69 EUR. As of today, Dividend Yield (TTM)% is 0.69%. Tracking SARTORIUS STEDIM BIOTECH S.A. dividends might help you take more informed decisions.
SARTORIUS STEDIM BIOTECH S.A. dividend yield was 0.29% in 2023, and payout ratio reached 20.53%. The year before the numbers were 0.48% and 15.15% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, 56S1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SARTORIUS STEDIM BIOTECH S.A. stock right from TradingView charts — choose your broker and connect to your account.
56S1 reached its all-time high on Sep 13, 2021 with the price of 557.20 EUR, and its all-time low was 51.10 EUR and was reached on Oct 18, 2017.
See other stocks reaching their highest and lowest prices.
As of Apr 27, 2024, the company has ‪10.66 K‬ employees. See our rating of the largest employees — is SARTORIUS STEDIM BIOTECH S.A. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SARTORIUS STEDIM BIOTECH S.A. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SARTORIUS STEDIM BIOTECH S.A. stock shows the strong sell signal. See more of SARTORIUS STEDIM BIOTECH S.A. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on SARTORIUS STEDIM BIOTECH S.A. future price: according to them, 56S1 price has a max estimate of 360.00 EUR and a min estimate of 150.00 EUR. Read a more detailed SARTORIUS STEDIM BIOTECH S.A. forecast: see what analysts think of SARTORIUS STEDIM BIOTECH S.A. and suggest that you do with its stocks.